FIGURE 3
Comparison of eGFR evolution in patients receiving Ifosfamide or combination of Ifosfamide + Cisplatin using MDRD formula. (A) Global evolution of eGFR at start (D0) and after one, six, twelve months (M1, M6, M12) and at last follow-up (*P < 0.05). (B) Comparison of initial eGFR (D0) and eGFR at last follow-up between patients receiving Ifosfamide or Ifosfamide+cisplatin (*P < 0.05). D0, Day 0; M1, M6, M12, Months 1, 6, 12.

Comparison of eGFR evolution in patients receiving Ifosfamide or combination of Ifosfamide + Cisplatin using MDRD formula. (A) Global evolution of eGFR at start (D0) and after one, six, twelve months (M1, M6, M12) and at last follow-up (*P < 0.05). (B) Comparison of initial eGFR (D0) and eGFR at last follow-up between patients receiving Ifosfamide or Ifosfamide+cisplatin (*P < 0.05). D0, Day 0; M1, M6, M12, Months 1, 6, 12.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close